X0609 4 2026-09-03 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001950232 Reardon Andrew false 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 0 1 0 0 CLO & Secretary 1 Common Stock 2026-09-03 4 S 0 300 283.9854 D 41214 D Common Stock 2026-09-03 4 S 0 1800 285.1671 D 39414 D Common Stock 2026-09-03 4 S 0 2115 286.3589 D 37299 D Common Stock 2026-09-03 4 S 0 385 287.5253 D 36914 D Common Stock 2026-09-03 4 S 0 400 288.9792 D 36514 D The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.4300 to $284.1550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.7500 to $285.7000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.8000 to $286.7700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.0500 to $287.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.5500 to $289.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Andrew Reardon 2026-09-08